MGX (Metagenomi Therapeutics) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.22
GF Value $0.74
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

MGX
10GF Score
Metagenomi Therapeutics Inc MGX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Metagenomi Therapeutics (MGX) Overvalued in 2026?

Based on GuruFocus' analysis, Metagenomi Therapeutics stock appears to be overvalued. The current stock price of $1.22 is trading 64.9% above its estimated GF Value™ of $0.74. GuruFocus considers Metagenomi Therapeutics to be Significantly Overvalued.

Key valuation signals for MGX:

  • FFO:
  • GF Value™: $0.74 vs. price of $1.22 (64.9% above fair value)
  • GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the MGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.22
Price
$0.74
GF Value